Black Diamond Therapeutics (NASDAQ:BDTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Wedbush reiterated an outperform rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, August 7th. Piper Sandler reiterated an overweight rating and set a $12.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, July 3rd. Finally, Raymond James began coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an outperform rating and a $20.00 price target on the stock.

Black Diamond Therapeutics Trading Down 2.6 %

NASDAQ BDTX opened at $5.62 on Wednesday. The business’s 50 day moving average is $5.53 and its two-hundred day moving average is $5.30. The stock has a market capitalization of $317.59 million, a price-to-earnings ratio of -3.39 and a beta of 2.49. Black Diamond Therapeutics has a 12-month low of $1.62 and a 12-month high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts forecast that Black Diamond Therapeutics will post -1.42 earnings per share for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bellevue Group AG raised its position in shares of Black Diamond Therapeutics by 4.9% during the 4th quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock worth $23,986,000 after purchasing an additional 400,000 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Black Diamond Therapeutics during the second quarter worth $3,891,000. Affinity Asset Advisors LLC acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth $3,029,000. TD Asset Management Inc lifted its position in shares of Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock valued at $1,241,000 after acquiring an additional 195,464 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Black Diamond Therapeutics by 24.1% during the second quarter. Renaissance Technologies LLC now owns 263,900 shares of the company’s stock valued at $1,230,000 after acquiring an additional 51,300 shares during the last quarter. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.